Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer
ConclusionFavorable prognosis, with fewer disturbances from other factors such as the use of abiraterone or/and enzalutamide, PSA changes, and BSI, was attainable in cases when the mCRPC patient demonstrated flare phenomenon. Follow-up bone scintigraphy at least every 3 months could help to determine the prognosis of patients with bone metastasis of mCRPC.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Nuclear Medicine | PET Scan | Prostate Cancer | Study | Taxotere